ISOXILAN Isoxsuprine Hydrochloride 5mg / mL Solution for IM/IV Injection 2mL 1's
Indications/Uses
An adjunct therapy in the treatment of peripheral vascular disease such as arteriosclerosis obliterans, thromboangiitis obliterans (Buerger's disease), and Raynaud's disease.
For the relief of symptoms associated with cerebrovascular insufficiency.
Dosage/Direction for Use
Maintain patients in preterm labor in the lateral position during infusion.
Monitor blood pressure (maternal) and heart rate (maternal and fetal) regularly during infusion and reduce the rate of infusion or discontinue infusion if prolonged fall in blood pressure occurs.
Circulatory Disturbances: See Table 2.
IM administration may be used for the initial control of acute severe symptoms, after which patients are maintained on oral therapy.
Overdosage
Overdosage with the oral format should be managed by gastric lavage. A nonselective β-blocker may be administered intramuscularly if necessary.
Administration
Contraindications
Parenteral use of isoxsuprine hydrochloride is also contraindicated in the following conditions: Hypotension; Tachycardia; Premature detachment of the placenta; Immediately postpartum; Premature labor if there is infection.
Special Precautions
To avoid pulmonary edema in women being treated for premature labor, very carefully monitor the patient's state of hydration, and cardiac and respiratory function. Keep fluid infusion volume to the minimum. For infusion, hypotonic dextrose is preferred over isotonic saline solution. Discontinue isoxsuprine immediately and institute diuretic therapy when signs of pulmonary edema develop.
Use in Children: lsoxsuprine is not indicated for pediatric patients.
Use in Elderly: No specific information is available on the use of isoxsuprine in elderly patients. lsoxsuprine may reduce tolerance to cold temperatures in these patients.
Use In Pregnancy & Lactation
Use isoxsuprine in pregnant women only when the potential benefit outweighs the potential risk to mother and infant.
There are no reports of problems with isoxsuprine in breastfeeding babies.
Adverse Reactions
Parenteral isoxsuprine administration can result in tachycardia, palpitations, hypotension, dizziness, and flushing. These can be controlled by dose reduction and by supine position of the patient. These effects are reversed, if necessary, by parenteral administration of noradrenaline.
Isoxsuprine may also cause slight increase in fetal heart rate if used as IV infusion in premature labor.
Drug Interactions
Storage
Action
Isoxsuprine also relaxes uterine smooth muscle and is valuable in arresting contractions in threatened abortion and premature labor.
Pharmacokinetics: Isoxsuprine is almost completely absorbed from the gastrointestinal tract after oral administration and peak plasma concentrations occur within 1 hour and persist for about 3 hours. lsoxsuprine's mean plasma half-life is about 1.25 hours. It crosses the placenta.
Isoxsuprine is conjugated partially in the body and is excreted in urine. Isoxsuprine's fecal excretion is negligible.
No data is available on the onset of effect and peak plasma concentration of isoxsuprine hydrochloride when administered parenterally. With intramuscular (IM) injection, isoxsuprine's effect lasts for 3 to 4 hours.
MedsGo Class
Features
- Isoxsuprine